RegulatoryJun 24, 2026, 08:46 AM
NeOnc Secures Second UAE IND for NEO100, Expands Clinical Trials
AI Summary
NeOnc Technologies Holdings has secured its second Investigational New Drug (IND) authorization from the United Arab Emirates for NEO100, its lead intranasal therapy candidate for recurrent high-grade gliomas. This approval, which spans adult Phase 1-2 studies and a pediatric development pathway, follows an earlier UAE IND for its NEO212 program, significantly expanding its international regulatory footprint. The company anticipates reporting topline results from its fully enrolled NEO100-01 Phase 2a trial by the end of July. Additionally, insider purchases by the CEO and institutional interest highlight growing confidence in the company's prospects.
Key Highlights
- NeOnc secured its second Investigational New Drug (IND) authorization from the UAE for NEO100.
- The NEO100 authorization covers three clinical protocols, including Phase 1-2 adult studies and a pediatric pathway.
- This follows a separate UAE IND authorization for the company's NEO212 program announced earlier in June.
- Topline results from the NEO100-01 Phase 2a trial are expected by the end of July.
- Chairman and CEO Amir Heshmatpour invested over $500,000 of personal capital in recent weeks.
- Total insider purchases are approaching $1 million over the past year.
- The company has access to a $75 million at-the-market facility and a $10 million line of credit.
Price Impact
More from NTHI